Strengthening commercial and R&D in the US @Novartis
Strengthening commercial and R&D in the US  @Novartis
Uploaded January 2023 | Updated November 2026, 2 hours ago
Novartis is transforming into a ‘pure-play’ Innovative Medicines company.

In a recent Meet Novartis Management Investor Relations session, Rod Wooten, Head of Global Product Strategy & Capabilities at Novartis outlines how strengthening our commercial and R&D interplays in the US is a critical component of our strategic focus and long-term performance.

Our refreshed strategy and the role of the US in strengthening our commercial and R&D approach is summarized in this short extract.

Meet Novartis Management
Event Date: September 22, 2022
Investors Page: bit.ly/3HjdDWX
Link to Novartis Strategy: bit.ly/3iP8cpp

Disclaimer: Meet Novartis Management event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: bit.ly/3HiI7IO

Follow @Novartis on Twitter: twitter.com/Novartis
Follow Novartis on LinkedIn: linkedin.com/company/novartis
Strengthening commercial and R&D in the USWorld Chagas Disease DayFocused Disease Areas for a Stronger Business ModelLiving with advanced prostate cancerWhat does belonging mean to you? Jacob’s story30 years of NovartisNovartis – Who We AreCommunity Health Takes a Village | screening in the Barber’s ChairPride 2026: Impact starts with usWorld Refugee Day: Rebuilding lives doesn’t happen alone, it takes a communitySeries Trailer: Dr John Tsai in conversation with cardiologist Dr Steven NissenRelax your tight end.
Novartis |

Strengthening commercial and R&D in the US

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER